The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2023
Filed:
Nov. 18, 2020
Applicant:
University of Iowa Research Foundation, Iowa City, IA (US);
Inventors:
Anil K. Chauhan, Iowa City, IA (US);
Nirav A. Dhanesha, Iowa City, IA (US);
Assignee:
UNIVERSITY OF IOWA RESEARCH FOUNDATION, lowa City, IA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/10 (2006.01); A61K 38/39 (2006.01); A61P 9/10 (2006.01); A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61P 29/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 9/00 (2006.01); C07K 14/47 (2006.01); C07K 7/08 (2006.01); C07K 14/78 (2006.01); C07K 14/46 (2006.01); C07K 14/705 (2006.01); C07K 14/52 (2006.01);
U.S. Cl.
CPC ...
A61K 38/10 (2013.01); A61K 38/1703 (2013.01); A61K 38/1709 (2013.01); A61K 38/1774 (2013.01); A61K 38/1866 (2013.01); A61K 38/19 (2013.01); A61K 38/39 (2013.01); A61K 39/3955 (2013.01); A61P 9/10 (2018.01); A61P 29/00 (2018.01); A61K 9/0019 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 7/08 (2013.01); C07K 14/46 (2013.01); C07K 14/47 (2013.01); C07K 14/4703 (2013.01); C07K 14/52 (2013.01); C07K 14/70503 (2013.01); C07K 14/78 (2013.01); C07K 16/2842 (2013.01); C07K 2317/76 (2013.01);
Abstract
The invention provides a method and kits for inhibiting integrin α9β1 activity comprising contacting integrin α9β1 or a binding partner of integrin α9β1 with an isolated anti-integrin α9 inhibitor, wherein the integrin α9β1 activity is inhibited. In certain aspects, the present invention provides a novel intervention by targeting integrin α9β1 with a functional blocking inhibitor (e.g., peptides or antibodies) to limit brain damage following reperfusion after ischemic stroke.